NCT04745143RecruitingPhase 2
Monotherapy of an NMDA Enhancer for Schizophrenia
Source: ClinicalTrials.gov · Last updated 24 Mar 2026
Brief summary (registry, in English)
Previous studies found that some NMDA-enhancing agent was able to augment antioxidant activity and its adjunctive therapy was better than placebo in reducing clinical symptoms and cognitive deficits and revealed favorable safety in patients with chronic schizophrenia. Of note, a substantial portion of schizophrenia patients refuse or cannot tolerate antipsychotics due to poor response or severe side effects. Therefore, this study aims to examine the efficacy and safety of an NMDA enhancer (NMDAE) as a monotherapy for the treatment of schizophrenia.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 14 Jan 2021
- Start date
- 1 Jan 2018
- Primary completion date
- 30 Sept 2027
- Lead sponsor
- China Medical University Hospital
- Diseases
- Schizophrenia
- NCT number
- NCT04745143
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 80
- From 1 Jan 2018 to the primary completion date, 30 Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Current substance abuse or history of substance dependence in the past 3 months
- History of epilepsy, head trauma, stroke or other serious medical or neurological illness which may interfere with the study
Lab values
- Clinically significant laboratory screening tests
Other
- Use of depot antipsychotic in the past 3 months;
- Pregnancy or lactation
- Inability to follow protocol
Who the study is looking for
- Have a DSM-5 (American Psychiatric Association) diagnosis of schizophrenia
- Refuse or are unable to tolerate antipsychotics due to poor response or adverse effects
- PANSS total score ≥ 60
- Free of antipsychotic drugs for at least 1 week
- Agree to participate in the study and provide informed consent
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Psychiatry, China Medical University Hospital Coordinator of this site? Confirm its status | Taichung | Taiwan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.